MaxCyte Webinars

  1. Cell Therapy's Current Manufacturing Challenges 4/15/2025

    In this segment, Cell & Gene’s Chief Editor, Erin Harris, welcomes the audience and introduces the expert panelists, Rohit Ingale, Head of Manufacturing & MSAT, Arcellx and David O’Donnell, Vice President, Head of Manufacturing, Vor Bio.

  2. Epitope Base Editing CD45 In Hematopoietic Cells Enables Universal Blood Cancer Immune Therapy 11/22/2024

    Researchers developed base-edited CAR T cells and CD45-edited stem cells to create universal blood cancer immunotherapy, showcasing efficacy while minimizing toxicity using MaxCyte electroporation technology.

  3. Unlocking The Potential Of Electroporation 11/22/2024

    Electroporation enables genetic research by introducing material into cells, advancing disease modeling, gene therapy, and ion channel studies.

  4. Overcome The Limitations Of Conventional Transfection With Electroporation 11/22/2024

    Learn how electroporation technology improves gene editing efficiency, reduces cell death, and enables scalable workflows for cell therapy, screening, and bioproduction in this informative webinar.

  5. Audience Q&A | Inside The Most Promising Non-Viral Approaches To Genetic Engineering 11/9/2024

    Expert panelists, Dr. Robert Hariri, Chairman, founder, and CEO of Celularity, and Paul Kopesky, Ph.D., VP of Cell Therapy Process Development at Beam Therapeutics, provided detailed responses to our audience questions on electroporation, CRISPR, delivery technologies beyond LNPs, CAR T-cell therapy, and more.

  6. Electroporation As A Method For Genetic Modification 11/9/2024

    In this clip, Dr. Robert Hariri, Chairman, founder, and CEO of Celularity, and Paul Kopesky, Ph.D., VP of Cell Therapy Process Development at Beam Therapeutics explain why electroporation has a higher gene editing efficiency than that of the viral vector method.

  7. NK Cells' Role In Non-Viral Approaches To Genetic Engineering 11/9/2024

    Here, Dr. Robert Hariri, Chairman, founder, and CEO of Celularity, and Paul Kopesky, Ph.D., VP of Cell Therapy Process Development at Beam Therapeutics each share their take on the primary challenge to modifying NK cells.

  8. Base Editing's Advantages When Combined With Non-Viral Delivery Methods 11/9/2024

    In this segment, Paul Kopesky of Beam Therapeutics shares information on the advantages base editing has over other gene editing approaches when combined with non-viral delivery methods as well as how Beam addresses the challenge of achieving therapeutic levels of editing and target tissues using non-viral delivery systems.

  9. Safety And Efficacy Advancements In Genome Editing 11/9/2024

    Paul Kopesky, Ph.D., VP of Cell Therapy Process Development at Beam Therapeutics shares his take on the high frequency of productive edits for base editing. In addition, Celularity’s Chairman, Founder, and CEO, Dr. Robert Hariri, shares how he sees non-viral gene delivery methods potentially enhancing cell therapy platforms.

  10. Non-Viral Tools For Genome Engineering 11/9/2024

    In this segment, Dr. Robert Hariri, Chairman, founder, and CEO of Celularity, and Paul Kopesky, Ph.D., VP of Cell Therapy Process Development at Beam Therapeutics each share their own take on the tools, platforms, and non-viral approaches they have used for genome engineering of cell therapeutics.